Schneider BJ - Search Results

1

High-Throughput Label-Free Isolation of Heterogeneous Circulating Tumor Cells and CTC Clusters from Non-Small-Cell Lung Cancer Patients.

Zeinali M, Lee M, Nadhan A, Mathur A, Hedman C, Lin E, Harouaka R, Wicha MS, Zhao L, Palanisamy N, Hafner M, Reddy R, Kalemkerian GP, Schneider BJ, Hassan KA, Ramnath N, Nagrath S. Zeinali M, et al. Among authors: schneider bj. Cancers (Basel). 2020 Jan 3;12(1):127. doi: 10.3390/cancers12010127. Cancers (Basel). 2020. PMID: 31947893 Free PMC article.

2

False-positive findings with positron emission tomography in the staging of non-small-cell lung cancer.

Schneider BJ, Avram AM, Shulkin BL, Kalemkerian GP. Schneider BJ, et al. Clin Adv Hematol Oncol. 2005 Jul;3(7):571-3. Clin Adv Hematol Oncol. 2005. PMID: 16167039 No abstract available.

3

Differentiation between carcinoid and sarcoid with F-18 FDG PET and In-111 pentetreotide.

Avram AM, Mackie GC, Schneider BJ, Kalemkerian GP, Shulkin BL. Avram AM, et al. Among authors: schneider bj. Clin Nucl Med. 2006 Apr;31(4):197-200. doi: 10.1097/01.rlu.0000204200.66112.a9. Clin Nucl Med. 2006. PMID: 16550010

4

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site.

Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM. Schneider BJ, et al. Cancer. 2007 Aug 15;110(4):770-5. doi: 10.1002/cncr.22857. Cancer. 2007. PMID: 17594717 Free article. Clinical Trial.

5

Phase II study of celecoxib and docetaxel in non-small cell lung cancer (NSCLC) patients with progression after platinum-based therapy.

Schneider BJ, Kalemkerian GP, Kraut MJ, Wozniak AJ, Worden FP, Smith DW, Chen W, Gadgeel SM. Schneider BJ, et al. J Thorac Oncol. 2008 Dec;3(12):1454-9. doi: 10.1097/JTO.0b013e31818de1d2. J Thorac Oncol. 2008. PMID: 19057272 Free PMC article. Clinical Trial.

6

Phase II trial of fenretinide (NSC 374551) in patients with recurrent small cell lung cancer.

Schneider BJ, Worden FP, Gadgeel SM, Parchment RE, Hodges CM, Zwiebel J, Dunn RL, Wozniak AJ, Kraut MJ, Kalemkerian GP. Schneider BJ, et al. Invest New Drugs. 2009 Dec;27(6):571-8. doi: 10.1007/s10637-009-9228-6. Epub 2009 Feb 19. Invest New Drugs. 2009. PMID: 19225720 Clinical Trial.

7

Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.

Schneider BJ, Kalemkerian GP, Ramnath N, Kraut MJ, Wozniak AJ, Worden FP, Ruckdeschel JC, Zhang X, Chen W, Gadgeel SM. Schneider BJ, et al. Clin Lung Cancer. 2010 Jul 1;11(4):223-7. doi: 10.3816/CLC.2010.n.028. Clin Lung Cancer. 2010. PMID: 20630823 Clinical Trial.

8

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S, Dunn R, Hussain M. Schneider BJ, et al. Invest New Drugs. 2012 Feb;30(1):249-57. doi: 10.1007/s10637-010-9503-6. Epub 2010 Aug 5. Invest New Drugs. 2012. PMID: 20686817 Clinical Trial.

9

Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer.

Schneider BJ, Gadgeel SM, Ramnath N, Wozniak AJ, Dy GK, Daignault S, Kalemkerian GP. Schneider BJ, et al. J Thorac Oncol. 2011 Jun;6(6):1117-20. doi: 10.1097/JTO.0b013e31821529c3. J Thorac Oncol. 2011. PMID: 21512407 Free article. Clinical Trial.

10

Personalized Therapy of Small Cell Lung Cancer.

Schneider BJ, Kalemkerian GP. Schneider BJ, et al. Adv Exp Med Biol. 2016;890:149-74. doi: 10.1007/978-3-319-24932-2_9. Adv Exp Med Biol. 2016. PMID: 26703804 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

166 results

Search Page